Spur Therapeutics

Spur Therapeutics, formerly known as Freeline Therapeutics, is a clinical-stage biotechnology company developing gene therapies for chronic and debilitating diseases. In June 2024, Freeline Therapeutics acquired SwanBio Therapeutics, and the merged entity was rebranded as Spur Therapeutics. The new company combines the pipelines and expertise of both firms, with founding shareholder Syncona committing an additional $50 million to support the expanded operations. The company was founded in 2015 and is headquartered in Stevenage, UK, with operations in the United States.

The company is led by CEO Michael Parini, who joined in 2021, and the board includes Chairman Chris Hollowood, CEO of Syncona, and Director John Tsai, former Executive Chair of SwanBio. Spur focuses on optimizing every component of its product candidates to advance the potential of gene therapy. The business model centers on developing and advancing a pipeline of gene therapy candidates through clinical trials to address high unmet medical needs. Its strategy includes moving beyond rare diseases into more prevalent conditions.

Spur's lead product candidate is FLT201, a gene therapy for Gaucher disease type 1, which is poised to enter a Phase 3 trial in 2025. Following the acquisition of SwanBio, Spur's pipeline now includes SBT101, a Phase 1/2 clinical-stage candidate for Adrenomyeloneuropathy (AMN), a neurodegenerative disease with no approved treatments. The company is also leveraging its technology for a research program in GBA1-linked Parkinson's disease and is developing candidates for cardiovascular diseases, such as chronic heart failure.

Keywords: gene therapy, biotechnology, Gaucher disease, Parkinson's disease, adrenomyeloneuropathy, chronic diseases, AAV gene therapy, central nervous system disorders, neurodegenerative diseases, cardiovascular disease, clinical-stage, FLT201, SBT101, Syncona, genetic medicine, lysosomal storage disorders, AAV technology, transgene, clinical trials, rare diseases